[1] 肖湘生, 李成州, 刘士远, 李惠民. 肺癌的CT诊断 [J]. 中国医学计算机成像杂志 2001.doi:10.3969/j.issn.1006-5741.2001.03.007 [2] 郑三, ZHENG San. 多肿瘤标志物蛋白芯片检测系统对肺癌的诊断价值 [J]. 中国热带医学 2006.doi:10.3969/j.issn.1009-9727.2006.05.017 [3] 刘天舟, 张琳, 王庆芳, 冯斐斐, 聂广金, 吴维超, 王静, 路太英, LIU Tianzhou, ZHANG Lin, WANG Qingfang, FENG Feifei, NIE Guangjin, WU Weichao, WANG Jing, LU Taiying. 血清CEA、NSE、SCC-Ag和CYFRA21-1联合检测对肺癌诊断的价值 [J]. 郑州大学学报(医学版) 2010.doi:10.3969/j.issn.1671-6825.2010.05.035 [4] GRANVILLE C A, DENNIS P A. An overview of lung cancer genomics and proteomics [J]. American Journal of Respiratory Cell and Molecular Biology 2005, 32(03). [5] MULSHINE J L, SULLIVAN D C. Clinical practice lung cancer screening [J]. New England Journal of Medicine 2005, 352(01). [6] 杨桐树, 李文辉, 孙喜文, 梁欢. 胸腔积液5种肿瘤标志物联合检测在肺癌诊断中的价值 [J]. 2010. [7] Takahashi H, Kurishima K, Ishikawa H, Kagohashi K, Kawaguchi M, Satoh H. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. [J]. Anticancer Research: International Journal of Cancer Research and Treatment 2010, 9(9). [8] LEE G, GE B, HUANG T K. Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients [J]. Cancer Biomark 2010, 6(02). [9] 江红, 李佩章, 雷考宁, 刘志民. 血清肿瘤标志物联合检测提高肺癌诊断的价值 [J]. 中华实用诊断与治疗杂志 2009. [10] Holdenrieder S, von-Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. [J]. Clinical cancer research: an official journal of the American Association for Cancer Research 2008, 23(23). |